Full Press Release Details
THIS ANNOUNCEMENT CONTAINS INSIDE
THE PURPOSES OF ARTICLE 7 OF REGULATION (EU) NO 596/2014
Tiziana Life Sciences plc
Exercise of Warrants & Issue of Equity
December 2018 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), a biotechnology company focusing on the discovery
and development of innovative therapeutics for inflammation and oncology indications, announces that further to its announcement
regarding a temporary reduction to exercise prices of outstanding warrants issued on 20 November 2018, it has received a notification
from warrant holders to exercise warrants over 54,000 ordinary shares of nominal value 0.03 each in the capital of the Company
("Ordinary Shares") at an exercise price in the amounts specified below, providing the Company with gross proceeds
| Number of Warrants | Current Exercise Price | Proposed New Exercise Price | Amount raised | |||
| 30,000 | 1.05 per share | 0.75 | 22,500.00 | |||
| 17,334 | 2.50 per share | 0.80 | 13,867.20 | |||
| 3,333 | 1.60 per share | 0.78 | 2,599.74 | |||
| 3,333 | 1.60 per share | 0.78 | 2,599.74 | |||
| 54,000 | 41,566.68 |
Application will be made to the London
Stock Exchange to admit the 54,000 new Ordinary Shares to trading on AIM. Admission of the new Ordinary Shares is expected
to occur on or around 14 December 2018 ("Admission"). The new Ordinary Shares will rank pari passu with
the existing Ordinary Shares.
Following Admission, the issued share capital
of the Company will be 136,463,818 Ordinary Shares and this figure may be used by shareholders as a denominator for the calculations
by which they will determine if they are required to notify their interest in, or change to their interest, the Company, under
the Disclosure Guidance and Transparency Rules published by the UK Financial Conduct Authority. There are no Ordinary Shares
held in treasury. Each Ordinary Share entitles the holder to a single vote at general meetings of the Company.
The person who arranged for release of
this announcement on behalf of the Company was Tiziano Lazzaretti, Chief Financial Officer of Tiziana.
About Tiziana Life Sciences
Tiziana Life Sciences plc is a UK biotechnology
company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology. In
addition to Milciclib, the Company is also developing Foralumab for liver diseases. Foralumab is the only fully human anti-CD3
monoclonal antibody in clinical development in the world. This Phase 2 compound has potential application in a wide range of autoimmune
and inflammatory diseases, such as nonalcoholic steatohepatitis (NASH), primary biliary cholangitis (PBS), ulcerative colitis,
multiple sclerosis, type-1 diabetes (T1D), inflammatory bowel disease (IBD), psoriasis and rheumatoid arthritis, where modulation
of a T-cell response is desirable.
For further enquiries:
| Tiziana Life Sciences plc | +44 (0)20 7493 2853 |
| Gabriele Cerrone, Chairman and founder | |
| Cairn Financial Advisers LLP (Nominated adviser) | +44 (0)20 7213 0883 |
| Liam Murray / Jo Turner |